Please assess the completion status of the following clinical trial:

Trial Title: Perindopril Amlodipine for the Treatment of Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Essential hypertension~* For female subjects, a negative serum pregnancy test~* Ability to provide written informed consent~Exclusion Criteria:~* Night shift workers whose work hours include midnight to 4:00 a.m.~* Secondary hypertension~* An arm size that precludes the use of the digital blood pressure monitor cuff (arm size \> 42 cm)~* Renal dysfunction, severe renal impairment, bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, subjects with only 1 kidney, or post-renal transplant subjects~* Female subjects who are pregnant, planning to become pregnant~* History of malignancy within 5 years~* Primary aldosteronism~* Heart failure (NYHA functional class 3-4), hypertrophic obstructive cardiomyopathy, or hemodynamically relevant stenosis of the aortic or mitral valve~* Significant cardiac arrhythmias, MI, stroke, CABG, PTCA, unstable angina~* Known hypersensitivity to any component of the study drugs~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- XOMA 985 (Type: EXPERIMENTAL): fixed-dose combination of perindopril arginine/amlodipine besylate(PERa/AMLb)
- Amlodipine Besylate (AMLb) (Type: ACTIVE_COMPARATOR): None
- Perindopril Erbumine (PERe) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).